Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
Hereditary ovarian carcinomas demonstrate better NACT outcomes in <i>BRCA2</i> vs. <i>BRCA1</i> mutation carriers. The opposite trend is observed in BC, which is likely to be attributed to a high frequency of triple-negative disease in <i>BRCA1</i>- but not <i>BRCA2</i>-associated BCs. Triple-negative receptor status rather than <i>BRCA1</i>/<i>2</i> status is the strongest predictor of response to NACT in BC.
Authors
- Anna D. Shestakova (ORCID: https://orcid.org/0000-0003-0649-9693)
- Петр Владимирович Криворотько (ORCID: https://orcid.org/0000-0002-4898-9159)
- Анна Петровна Соколенко (ORCID: https://orcid.org/0000-0001-6304-1609)
- T. V. Gorodnova (ORCID: https://orcid.org/0000-0003-1719-7498)
- Евгений Наумович Имянитов (ORCID: https://orcid.org/0000-0003-4529-7891)
- A. O. Nyuganen (ORCID: https://orcid.org/0000-0003-2685-5093)
- Александр Олегович Иванцов (ORCID: https://orcid.org/0000-0001-6279-2312)
- D. A. Enaldieva (ORCID: https://orcid.org/0000-0002-2773-3111)
- А. М. Belyaev (ORCID: https://orcid.org/0000-0001-5580-4821)
- И. В. Берлев (ORCID: https://orcid.org/0000-0001-6937-2740)
Institutions
- Institute of Oncology NN Petrov (RU)
- Saint Petersburg State Pediatric Medical University (RU)
Publication Details
- Journal
- Exploration of Targeted Anti-tumor Therapy
- Published
- 2025-06-18
- DOI
- https://doi.org/10.37349/etat.2025.1002325
- Citations
- 2
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Russian Science Foundation